

Re: FOI 24/227 - Marketing Status of Levocarnitine Paediatric 30% Oral Solution

FOILicensing <FOILicensing@mhra.gov.uk>

Thu 28/03/2024 16:20

To [REDACTED]

Cc:MHRA Customer Services <MHRACustomerServices@mhra.gov.uk>;FOILicensing <FOILicensing@mhra.gov.uk>

Dear [REDACTED]

Thank you for your Freedom of Information request of 5 March 2024.

Your request

Please could you disclose

- *If Levocarnitine Paediatric 30% Oral Solution (PL 48053/0005) is currently marketed in the UK?*
- *The date this product was claimed to be marketed in the UK / If the product is not marketed, please could you provide me with the date when the marketing status was last changed?*

Our response

I confirm that MHRA holds this information.

According to our records, Levocarnitine Paediatric 30% Oral Solution (PL 48053/0005) has been marketed in the UK since 14 April 2018.

The Freedom of Information Act only entitles you access to information – the information supplied is subject to Crown copyright, and there are some restrictions on its re-use. For information on the reproduction or re-use of MHRA information, please visit <https://www.gov.uk/government/publications/reproduce-or-re-use-mhra-information/reproduce-or-re-use-mhra-information>.

If you have a query about the information provided, please reply to this email

If you are dissatisfied with the handling of your request, you have the right to ask for an internal review. Internal review requests should be submitted within two months of the date you receive this response and addressed to: info@mhra.gov.uk

Please remember to quote the reference number above in any future communications.

If you were to remain dissatisfied with the outcome of the internal review, you would have the right to apply directly to the Information Commissioner for a decision. Please bear in mind that the Information Commissioner will not normally review our handling of your request unless you have first contacted us to conduct an internal review. The Information Commissioner can be contacted at:

Information Commissioner's Office
Wycliffe House
Water Lane
Wilmslow
Cheshire
SK9 5AF

Yours sincerely,

FOI Team

MHRA Customer Service

From: [REDACTED]
Sent: Tuesday, March 5, 2024 12:49 PM
To: MHRA Customer Services <MHRACustomerServices@mhra.gov.uk>
Subject: FOI 24/227 - Marketing Status of Levocarnitine Paediatric 30% Oral Solution

You don't often get email from [REDACTED] [Learn why this is important](#)

Dear Sir/Madam,

I am writing to request information under the freedom of information act.

Please could you disclose:

- If Levocarnitine Paediatric 30% Oral Solution (PL 48053/0005) is currently marketed in the UK?
- The date this product was claimed to be marketed in the UK / If the product is not marketed, please could you provide me with the date when the marketing status was last changed?

I look forward to receiving your feedback.

Kind regards,

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

Email: [REDACTED]

[REDACTED]

[REDACTED]

[REDACTED] This email and any files transmitted with it are confidential. If you are not the intended recipient, any reading, printing, storage, disclosure, copying or any other action taken in respect of this email is prohibited and may be unlawful. If you are not the intended recipient, please notify the sender immediately by using the reply function and then permanently delete what you have received. Incoming and outgoing email messages are routinely monitored for compliance with the Department of Health's policy on the use of electronic communications. For more information on the Department of Health's email policy, click [DHTermsAndConditions](#)